Inflammatory Bowel Disease Treatment Market (By Type: Ulcerative colitis, Crohn’s sickness; By Route of Administration: Oral [JAK inhibitors, ASAs, Corticosteroids, Others], Injectables [IL inhibitors, TNF-inhibitors, Anti-integrin, Others]; By Distribution Channel: Online, Hospital, Retail) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 190

According to Acumen Research and Consulting, the global Inflammatory Bowel Disease Treatment market is expected to grow at noteworthy CAGR around 4.1 % throughout the forecast period and reach around US$ 21.3 billion by 2026.

Bowel inflammation infection consists primarily of ulcerative colitis and Crohn's disease. Gastrointestinal disease is a group of inflammatory diseases. Inflammatory bowel diseases cause chronic and serious inflammation without any knowledgeable cause in the gastrointestinal tract. Ulcerative colitis primarily influences your internal lining, causing inflammation and lesions in the colon and rectum. Colitis disease Ulcerative colitis is a illness more frequently found than Crohn's. Crohn's condition is not limited to the large intestine and rectum, as it does to ulcerative colitis, it can impact every portion of the gastrointestinal tract from the mouth to the bowels and the anus.

Chronic pain and stress in the abdomen, persistent diarrhoea, sometimes rectal bleeding and fever are the frequent symptoms of IBD. In developed nations, the precise cause of inflammatory bowel illness is not well understood and these illnesses have shown elevated prevalence and incidence rates. Several medicines are prescribed for the symptoms of these illnesses, for example immunomodulators, corticosteroids, aminosalicyclates, biologic drugs like tNF-inhibitors and, to some extent, antibiotic medicines.

The report provides analysis of global Inflammatory Bowel Disease Treatment market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

Market Insights

The presence of highly inflammable bowel disease (IBD) pipeline goods is expected to drive the market over the predicted time span. Major players such as Shire, Abb Viee, Inc. and Celgene, Pfizer Inc., Eli Lilly and Company, and Gilead Sciences participate in R&D to implement and market better goods. It is estimated that the mechanism of action and effectiveness of pipeline goods such as Upadacitinib, Ozanimod, and Risankizumab. Another key factor in the general economy is the emergence of biological imbalances. Biosimilars are anticipated to be cheaper than biologics, making them in developing nations more available. One of the variables responsible for launching fresh biosimilars is the anticipated patent expiry of certain of the medicines.

In 2016, for example, the USA A biosimilar Inflectra comparable to Remicade with reduced competitive prices was endorsed by the FDA. The biological medicine Remicade, produced and approved in 1998 by Janssen Non-surgical is used mainly in the therapy of Crohn's disease and ulcerative colitis.

Type Stance

Two significant kinds of IBDs are Crohn's disease and ulceratory colitis. Due to the growing incidence of the disorder, Crohn's illness was the biggest segment in 2018. The incidence of CD was discovered to be around 3,1 to 14,6 instances per 100,000 people each year in 2018, with a prevalence of around 201 instances per 100,000 adolescents in the United States according to an article released by Jobson Medical Information LLC.

Ulcerative colitis, due to the existence of powerful pipeline goods, is thought to be the fastest increasing segment during the current year. In addition, the segment will increasingly be driven by the participation of important players in the field product development. Johnson & Johnson Services Inc. announced fresh information from their Phase III UNIFI survey in March 2019 which showed beneficial outcomes for adolescents with mild to serious colitis with STELARA.

Route of Administration Stance

Due to its effectiveness, injectables are regarded as the biggest segment. Moreover, biosimilars like Inflectra should develop to boost the development of the segment. This section is further split into IL, TNF, and anti-integrin inhibitors. The biggest sub-segment in 2018 was the TNF-inhibitors.

Due to the existence of powerful pipeline goods, the oral route is projected to be the fastest increasing segment in the forecost era. The oral section is further divided into inhibitors of ASAs, corticosteroids and JAK. In 2018, ASAs dominated the market, and JAK inhibitors are projected to be the fastest increasing segment in the forecast era.

Distribution Channel Stance

In 2018, the hospital-based and outpatient pharmacy segment dominated the market with an over 35% share. Crohn's disease and ulcerative colitis have been increasingly prevalent and the total amount of hospitals globally has increased. The most rapidly increasing segment in the prediction is estimated in the online pharmacy. Comfort, flexibility and comfort, which are increasing the income produced in this section, increase the trend of the online purchases and the demand for them. In addition, internet shopping provides multiple discounts, benefiting clients in addition. These variables should increase internet pharmaceutical demand during the forecast era.

Regional Stance

Due to the existence of important businesses and established health facilities, North America resulted the market in 2018. Due to the growing geriatric population and incidence of ulcerative colitis and Crohn's disease, the area is expected to continue to dominate the prediction years.

Europe was by area in 2018 the second-largest market for inflammatory bowel disease therapy. During the forecasted era the European market is anticipated to grow steadily due to the growing prevalence of inflammatory bowel illness, increased levels of alcohol abuse, unhealthy lifestyle practices and the growing incidence of anxiety and depression among adolescents. Additionally, the growth of the European market for inflammatory bowel diseases will probably be stimulated by variables such as an increased public efforts and research financing, the development of sophisticated therapy alternatives and the accessibility of favourable refund policy..

The incidence of CDs in 2018 was estimated to be roughly 3.2 to 14.6 instances per 100,000 persons per year, and the prevalence was about 201 instances per 100,000 adolescents in the USA, according to an article released by the Jobson Medical Information LLC. Asia Pacific, owing to the increased product approvals, is projected to be the highest growth region segment in the forecast period.

Market Segmentation

Global Inflammatory Bowel Disease Treatment Market, By Type

  • Ulcerative colitis
  • Crohn’s sickness

Global Inflammatory Bowel Disease Treatment Market, By Route of Administration

  • Oral
    • JAK inhibitors
    • ASAs
    • Corticosteroids
    • Others
  • Injectables
    • IL inhibitors
    • TNF-inhibitors
    • Anti-integrin
    • Others

Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel

  • Online
  • Hospital
  • Retail

Global Inflammatory Bowel Disease Treatment Market, By Geography

  • North America.
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

The market research study on “Inflammatory Bowel Disease Treatment Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Inflammatory Bowel Disease Treatment market segments with market dynamics and their impact. The report also covers basic technology development policies.

The study offers an assessment of the recent trends in each sub-segment from 2015 to 2026, with sales and development at the worldwide, regional and national levels. ARC divided the worldwide bowel disease therapy market report for the purposes of this research on a type basis, route of administration, distribution, regional as follows:

Key Players & Strategies

Some of the vital companies in this market are Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION; Takeda Pharmaceutical Company Limited; Innovate Biopharmaceuticals; COSMO PHARMACEUTICALS; and Gilead Sciences. They are concentrated mainly on regional expansion, strategic arrangements and new product research and development.

For example, Janssen Biotech Inc. signed a strategic agreement with Protagonist Therapeutics, Inc. in 2017 to develop the oral IL 23 receiver PTG-200 for the treatment of inflammatory bowel diseases, manufactured and marketed. The European Union authorized Pfizer Inc., in 2018, to treat mild to serious ulcerative colitis by XELJANZ for marketing.

Cart Summary